GSK and Pfizer RSV Vaccines for Pregnant Women Increased Risk of Preterm Births — GSK Ended Its Trials, but FDA Approved Pfizer Shots
GSK stopped developing a vaccine for pregnant women to protect newborns against syncytial virus (RSV) after identifying an increased risk of preterm births. Pfizer won approval of its nearly identical vaccine after the company said the increased rate of preterm births in its trials was statistically insignificant. GSK on Thursday provided more details on the…